Processing

Please wait...

Settings

Settings

1. WO1996004788 - ANTISENSE AND TRIPLEX THERAPEUTIC AGENTS AND METHODS

Publication Number WO/1996/004788
Publication Date 22.02.1996
International Application No. PCT/US1995/010055
International Filing Date 09.08.1995
Chapter 2 Demand Filed 07.03.1996
IPC
C07H 21/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
CPC
C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N 2310/15
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
15Nucleic acids forming more than 2 strands, e.g. TFOs
C12N 2310/3511
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
35Nature of the modification
351Conjugate
3511intercalating or cleaving agent
Applicants
  • ALTMAN, Sidney [US/US]; US
  • FIEDLER, Paul [US/US]; US
  • LEVINE, Robert, A. [US/US]; US
  • WARDLAW, Stephen, C. [US/US]; US
Inventors
  • ALTMAN, Sidney; US
  • FIEDLER, Paul; US
  • LEVINE, Robert, A.; US
  • WARDLAW, Stephen, C.; US
Agents
  • CARRIER, Robert, J.; Price, Heneveld, Cooper, DeWitt & Litton 695 Kenmoor, Southeast P.O. Box 2567 Grand Rapids, MI 49501, US
Priority Data
08/288,59310.08.1994US
08/389,49616.02.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTISENSE AND TRIPLEX THERAPEUTIC AGENTS AND METHODS
(FR) AGENTS ET PROCEDES DE THERAPIES ANTISENS ET TRIPLEX
Abstract
(EN)
Antisense and anti-gene oligonucleotides and modified oligonucleotides with plural intercalating molecules attached for use in antisense and triplex therapy. Virally infected blood, blood plasma or serum samples are rendered significantly less infectious while maintaining the integrity of the sample for clinical analysis. Synthetic strands of oligonucleotides, and/or nuclease-resistant derivatives of oligonucleotides having intercalating agent molecules attached thereto provide an additive for incorporation into a blood sample which is to undergo analytical tests and procedures. Sterilization of a significant number of intracellular target viruses in the sample renders the sample significantly less capable of infecting those handling it. An appropriate binding material additive, such as an antibody or aptamer, which is specific for epitopes or other binding sites on the free or extracellular target virus, may also be used, either alone or in combination with the intracellular strand ingredients.
(FR)
On décrit des oligonucléotides, antisens et anti-gène, et des oligonucleotides modifiés, auxquels sont rattachées plusieurs molécules d'intercalation, utiles dans des thérapies antisens et triplex. Du sang, du plasma sanguin ou des échantillons de sérum sont rendus nettement moins infectieux, lorsqu'ils sont infectés par des virus, tout en gardant leur intégrité aux fins d'analyse clinique. Des brins synthétiques d'oligonucléotides, et/ou des dérivés d'oligonucléotides résistant aux nucléases, se voient rattacher des molécules d'un agent d'intercalation et constituent un additif qu'on peut rajouter à un échantillon de sang devant subir des examens et procédures de type analytique. La stérilisation d'un nombre significatif de virus cibles intracellulaires présents dans l'échantillon rend celui-ci nettement moins susceptible d'infecter des personnes qui le manipulent. Un additif prenant la forme d'un élément de liaison approprié tel qu'un anticorps ou un aptamère, spécifique de certains épitopes ou sites de liaison présents sur des virus cibles libres ou extracellulaires, peut aussi convenir, seul ou combiné avec des ingrédients de brins cellulaires.
Latest bibliographic data on file with the International Bureau